Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly delivers “solid financial results”

Lilly delivers “solid financial results”

23rd July 2009

Lilly has announced “solid financial results” for the second quarter of 2009.

In a statement, the organisation explained that it has revised its full-year earnings per share guidance range to $4.14 (2.51 pounds) to $4.24 on a reported basis.

Additionally, the full-year 2009 pro forma non-GAAP earnings per share guidance range has been raised to $4.20 to $4.30 per share.

Commenting on the announcement, John Lechleiter, Lilly’s chairman and chief executive, said that the business remained strong during the second three-month period of 2009, with good operating leverage and “volume-driven revenue growth”.

“Lilly continues to deliver solid financial results notwithstanding the challenging global economic environment,” he added.

Mr Lechleiter also noted that sales of Alimta and Cymbalta were “particularly noteworthy” during the quarter.

Earlier this month, Lilly and Daiichi Sankyo announced that the Food and Drug Administration gave approval for Effient tablets to be used in the treatment of thrombotic cardiovascular events in acute coronary condition patients who are managed with percutaneous coronary intervention.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.